refractory leukemia

Showing 1 - 18 of 18

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)

Recruiting
  • Refractory Leukemia
  • CALGE-VEN- RIC-MBF
  • Shanghai, Shanghai, China
  • +2 more
May 22, 2023

Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded

Not yet recruiting
  • Refractory Leukemia
  • +4 more
  • STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
  • Dendritic Cell Vaccine
  • Miami, Florida
    University of Miami
Jan 23, 2023

T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)

Recruiting
  • T-lymphoblastic Lymphoma
  • +5 more
  • BCL2 Inhibitor plus IM2 regimen
  • Shanghai, Shanghai, China
    Shanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023

Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)

Recruiting
  • Recurrent Leukemia
  • Refractory Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Acute Leukemia, Recurrent Leukemia, Refractory Leukemia Trial in Columbus (Best Practice, Bright White Light Therapy, Survey

Recruiting
  • Acute Leukemia
  • +2 more
  • Best Practice
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 14, 2022

Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in

Not yet recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +3 more
  • Olverembatinib, APG-2575, Dexamethasone
  • Hefei, Anhui, China
  • +3 more
Aug 8, 2022

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

Solving Riddles Through Sequencing

Recruiting
  • Leukemia
  • +5 more
  • Next Generation Sequencing
  • Munich, Germany
    MLL Munich Leukemia Laboratory
Jan 19, 2022

Relapsed or Refractory Chronic Lymphocytic Leukemia

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Cona, Ferrara, Italy
  • +26 more
Jan 3, 2022

Relapse Leukemia, Refractory Leukemia Trial in Shenzhen (Allogeneic CD19 CAR-T cells)

Recruiting
  • Relapse Leukemia
  • Refractory Leukemia
  • Allogeneic CD19 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Dec 7, 2021

Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 2, 2021

Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR

Recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +6 more
  • CAR T-cell therapy
  • Singapore, Singapore
    Allen Yeoh Eng Juh
Sep 7, 2021

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia Trial in Chengdu (Modified anti-CD19 CAR T cells)

Active, not recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Leukemia
  • Modified anti-CD19 CAR T cells
  • Chengdu, Sichuan, China
    Sichuan University
Mar 17, 2021

Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia Trial in Vienna (Next generation functional drug screening,

Recruiting
  • Advanced Lymphoma
  • +4 more
  • Next generation functional drug screening
  • Comprehensive genomic profiling
  • Vienna, Austria
    Medical University of Vienna
Jul 10, 2020

Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia Trial in Beijing (Decitabine, mBU/CY and ATG, mBU/CY)

Recruiting
  • Stem Cell Transplant Complications
  • +2 more
  • Beijing, Beijing, China
    Peking University Institute of Hematology,Beijing
May 27, 2019

Refractory Leukemia, Acute Myelogenous Leukemia Trial in Worldwide (Panobinostat/LBH589)

Completed
  • Refractory Leukemia
  • Acute Myelogenous Leukemia
  • Chicago, Illinois
  • +39 more
Jan 8, 2017